BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dhiman RK, Grover GS, Premkumar M. Hepatitis C elimination: a Public Health Perspective. Curr Treat Options Gastro 2019;17:367-77. [DOI: 10.1007/s11938-019-00240-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Squires JE, Balistreri WF. Treatment of Hepatitis C: A New Paradigm toward Viral Eradication. The Journal of Pediatrics 2020;221:12-22.e1. [DOI: 10.1016/j.jpeds.2020.02.082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Premkumar M, Kumar Chawla Y. Chronic Hepatitis B: Challenges and Successes in India. Clin Liver Dis (Hoboken) 2021;18:111-6. [PMID: 34691396 DOI: 10.1002/cld.1125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Premkumar M, Anand AC. Overview of Complications in Cirrhosis. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.021] [Reference Citation Analysis]
4 Kong F, Wen X, Wen X, Wang X, Wu G, Lin S, Wang L, Xing H, Yan X, Zheng S, Ning Q, Wang Z, Zhang L, Lin J, Tong Z, Huang C, Su M, Tong L, Jia J, Xin Y, Zhu Q, Wang J, Chen L, Li X, Wu X, Niu D, Liu Q, Wei W, Zhang Y, Li G, Niu J. Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial. J Gastroenterol Hepatol 2021. [PMID: 33491236 DOI: 10.1111/jgh.15412] [Reference Citation Analysis]
5 Ghosh A, Mahintamani T, Premkumar M, Basu D, Singh V, Duseja A, Subodh Bn, Mohindra R, Sharma A, Arora SK. Multidisciplinary and Integrated Treatment for Substance Use Disorders and Hepatitis C in an Addiction Treatment Service in India. Indian Journal of Psychological Medicine. [DOI: 10.1177/02537176221086013] [Reference Citation Analysis]
6 Zhao Q, Jiang S, Li M, Yao L, Ma X, Li M, Wang C, Pan Y, Zhao H, Li B. Incidence trend and age-period-cohort analysis of reported hepatitis C among residents aged 30 to 79 in northeastern China, 2008 to 2017. Medicine (Baltimore) 2020;99:e22005. [PMID: 32899048 DOI: 10.1097/MD.0000000000022005] [Reference Citation Analysis]
7 Dhiman RK, Grover GS, Premkumar M, Roy A, Taneja S, Duseja A, Arora S; MMPHCRF Investigators. Outcomes of Real-World Integrated HCV Microelimination for People Who Inject Drugs: An expansion of the Punjab Model. EClinicalMedicine 2021;41:101148. [PMID: 34712928 DOI: 10.1016/j.eclinm.2021.101148] [Reference Citation Analysis]
8 Shahid M, Qadir A, Yang J, Ahmad I, Zahid H, Mirza S, Windisch MP, Shahzad-Ul-Hussan S. An Engineered Microvirin Variant with Identical Structural Domains Potently Inhibits Human Immunodeficiency Virus and Hepatitis C Virus Cellular Entry. Viruses 2020;12:E199. [PMID: 32054060 DOI: 10.3390/v12020199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Liu M, Chen HY, Luo L, Wang Y, Zhang D, Song N, Wang FB, Li Q, Zhang XL, Pan Q. Neutralization of IL-10 produced by B cells promotes protective immunity during persistent HCV infection in humanized mice. Eur J Immunol 2020;50:1350-61. [PMID: 32339264 DOI: 10.1002/eji.201948488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]